- Home
- ICMB vs JSPR Comparison
ICMB vs JSPR Comparison
Compare ICMB & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICMB | JSPR |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICMB | JSPR |
|---|---|---|
| Price | $0.74 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 86.2K | ★ 597.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.32 |
| 52 Week High | $3.12 | $3.52 |
Technical Indicators
Market Signals| Indicator | ICMB | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 22.88 | 63.21 |
| Support Level | N/A | $0.62 |
| Resistance Level | $1.29 | $1.02 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 0.02 | 80.51 |
Price Performance
Historical ComparisonAbout ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.